BioSpace News Archive

Agenus Inc., a leader in developing novel immunological agents to treat cancers, announced first-time and updated data from its ongoing botensilimab/balstilimab clinical programs in advanced colorectal cancer, neoadjuvant CRC, pancreatic cancer, non-small cell lung cancer, melanoma, and sarcoma.

Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® for up to one year in children aged 1 to 11 years with eosinophilic esophagitis was consistent.

Exelixis, Inc. announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors and a second cohort of patients with advanced extra-pancreatic NET.

Sutro Biopharma, Inc. announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with endometrial cancer, in a mini oral presentation at the 2023 European Society For Medical Oncology Congress in Madrid, Spain.

Seagen Inc. and Genmab A/S announced results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.